Can immunosuppressive drugs slow the progression of IgA nephropathy?

Γούμενος, Δ.; Ahuja, Manohar; Shortland, J. R.; Brown, C B

doi:10.1093/ndt/10.7.1173

Cited by 46 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results from previous studies regarding the effect of immunosuppressive treatment in the outcome of IgAN are controversial [21][22][23][24][25][26][27]. The first retrospective studies showed a beneficial effect of azathioprine in IgAN patients with advanced renal failure [21,22], and these studies were followed by prospective ones aiming to clarify the role of immunosupressants in the progression of IgAN [9,[23][24][25][26].…”

Section: Discussionmentioning

confidence: 99%

“…The first retrospective studies showed a beneficial effect of azathioprine in IgAN patients with advanced renal failure [21,22], and these studies were followed by prospective ones aiming to clarify the role of immunosupressants in the progression of IgAN [9,[23][24][25][26]. Aza given as maintenance treatment after a 3-month induction therapy with steroids and cyclophospamide stabilized renal function in patients with severe IgAN [8].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Steroids and azathioprine in the treatment of IgA nephropathy

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Steroids and azathioprine in the treatment of IgA nephropathy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Since 1990, corticosteroids, immunosuppressive agents, antiplatelet drugs, and anticoagulation have been used alone or in combination to treat IgAN 33–41 . However, there have been no reports comparing the efficacy of the above treatments.…”

Section: Iga Nephropathymentioning

confidence: 99%

Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment

Kawasaki

2011

Pediatrics International

View full text Add to dashboard Cite

Immunoglobulin A nephropathy (IgAN) is one of the most common causes of chronic glomerulonephritis (CGN) in the world. The proliferative and crescentic forms of IgA are found in up to 30% of cases and are associated with nephritic-range proteinuria, accelerated hypertension, and accelerated decline toward end-stage renal disease. On the other hand, Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and the deposition of IgA immune complexes. Renal involvement is the principal cause of morbidity and mortality in children with HSP. Two entity diseases are important as renal diseases in childhood. We herein review the mechanism of the onset and exacerbation of IgAN and HSP nephritis (HSPN) and its treatment.As to the pathogenesis, we found that CB4 provoked exacerbation of renal pathologic findings in hyper IgA mice via endothelial injury, g-interferon production, and dysfunction of the mesangial pathway and could possibly become one of the factors involved in the mechanism of the onset or evolution of human IgAN. As to the treatment of IgAN and HSPN, we evaluated the efficacy of multidrug combination therapy (prednisolone, warfarin, and dipyridamole, including mizoribine) for diffuse IgAN and the efficacy of methylprednisolone and urokinase pulse therapy plus immunosuppressive drugs for severe HSPN in children. These therapies were effective in ameliorating the proteinuria and histologic severity of patients with IgAN or HSPN. In future, detailed investigations into the pathogenesis of CGN and double-blind randomized control studies on children with IgAN or HSPN will be necessary.

show abstract

“… In patients with IgA nephropathy and nephrotic syndrome that have proved resistant to conventional treatment, clinical remission in selected patients has been reported following the use of cyclosporin, 1 azathioprine, 2 mycophenolate 3 and intravenous immunoglobulin, 4 ketoconazole 5 and mizobine. 6 These anecdotal reports do not provide conclusive evidence of their efficacy in preventing disease progression in IgA nephropathy and further studies are needed before these treatments can be recommended.…”

Section: Suggestions For Clinical Carementioning

confidence: 99%